Leukemia Research
Volume 27, Issue 3 , Pages 243-251 , March 2003

CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype

  • Karina L Silva

      Affiliations

    • Laboratório de Hematologia Celular e Molecular, Serviço de Hematologia, Hospital do Câncer (HC-I), Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
    • ,
  • Flavia C Vasconcelos

      Affiliations

    • Laboratório de Hematologia Celular e Molecular, Serviço de Hematologia, Hospital do Câncer (HC-I), Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
    • ,
  • Luis Fernando Marques-Santos

      Affiliations

    • Laboratório de Hematologia Celular e Molecular, Serviço de Hematologia, Hospital do Câncer (HC-I), Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
    • Laboratório de Imunologia Tumoral, Departamento de Bioquı́mica Médica, Universidade Federal do Rio de Janeiro (UFRJ), RJ, Brazil
    • ,
  • Jolie K Kwee

      Affiliations

    • Laboratório de Hematologia Celular e Molecular, Serviço de Hematologia, Hospital do Câncer (HC-I), Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
    • ,
  • Raquel C Maia

      Affiliations

    • Laboratório de Hematologia Celular e Molecular, Serviço de Hematologia, Hospital do Câncer (HC-I), Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55-21-2506-6198; fax: +55-21-2506-6725

Received 9 November 2001 ,Accepted 1 June 2002.

References 

  1. Ling V. Multi-drug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 1997;40:3–8
  2. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia. 2000;14:467–473
  3. List AF. Non-P-glycoprotein drug export mechanisms of multi-drug resistance. Sem. Hematol. 1997;34:24–29
  4. Shimada Y. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 1993;11:909–913
  5. Wall ME, Wani MC, Cook CE, Palmer KH, MacPhail AT, Sim GA. Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966;88:3888–3890
  6. Liu LF, Duann P, Lin C-T, D’Arpa P, Wu J. Mechanism of action of camptothecin. Ann. N.Y. Acad. Sci. 1996;803:44–49
  7. Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin. Cancer Res. 1995;1:1235–1244
  8. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 1988;21:71–74
  9. Del Bino G, Skierski JS, Darzynkiewicz Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res. 1990;50:5746–5750
  10. Kano K, Suzuki K, Akutsu M, Suda K, Inque Y, Yoshida M, et al.  Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer. 1992;50:604–610
  11. Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivatives in human leukemia HL-60 cells. Jpn. J. Cancer Res. 1993;84:566–573
  12. Cohen D, Adams DJ, Flowers JL, Wall ME, Wani MC, Manikumar G, et al.  Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. Leuk. Res. 1999;23:1061–1070
  13. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al.  Antitumor activity of 7-ethyl –10-[ 4-(1-piperidino)-1piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987;47:5944–5947
  14. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990;50:1715–1720
  15. Kantarjian HM, Beran M, Ellis A, Zwelling L, O’Brien S, Cazenave L, et al.  Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993;81:1146–1151
  16. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J. Combination chemoterapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin’s lymphoma. Ann. Oncol. 2000;11:115–116
  17. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 1990;8:1907–1912
  18. Tsuda H, Takatsuki K, Onho R, Masaoka T, Okada K, Shirakawa S, et al. Treatment of adult T-cell leukaemia–lymphoma with irinotecan hydrochloride (CPT-11). Br. J. Cancer 1994;70:771–774.
  19. Yang C-HJ, Horton JK, Cowan KH, Schneider E. Cross-resistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995;55:4004–4009
  20. Jansen WJM, Hulscher TM, Ark-Otte Jv, Giaccone G, Pinedo HM, Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multi-drug resistance-associated protein. Br. J. Cancer. 1998;77:359–365
  21. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, et al.  Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother. Pharmacol. 1997;39:417–423
  22. Hoki Y, Fujimori A, Pommier Y. Differential citotoxity of clinically important camptothencin derivatives in P-glycoprotein overexpressing cell lines. Cancer Chemother. Pharmacol. 1997;40:433–438
  23. Palissot V, Belhoussine R, Carpentier Y, Sebille S, Morjani H, Manfait M, et al.  Resistance to apoptosis induced by topoisomerase I inhibitors in multi-drug resistance HL60 leukemic cells. Biochem. Biophys. Res. Commun. 1998;245:918–922
  24. Chen Z-S, Sumizawa T, Furukawa T, Ono K, Tani A, Komatsu M, et al.  An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Lett. 1999;138:13–22
  25. Rumjanek VM, Lucena M, Campos MM, Marques-Silva VM, Maia RC. Multi-drug resistance in leukemias: the problem and some approaches to its circumvention. Ciência e Cultura. 1994;46:63–69
  26. Rumjanek VM, Trindade GS, Wagner-Souza K, Melete-de-Oliveira MC, Marques-Santos LF, Maia RC, et al.  Multi-drug resistance in tumor cells: characterization of the multi-drug resistant cell line K562-Lucena 1. Ann. Acad. Bras. Ci. 2001;73:57–69
  27. Tsuruo T, Lida H, Ohkochi E, Tsukagoshi S, Sakurai Y. Establishment and properties of a vincristine-resistance human myelogenous leukemia K562. Jpn. Cancer Res. (Gann). 1983;74:751–758
  28. Maia RC, Wagner K, Cabral RH, Rumjanek VM. Heparin reverses rhodamine-123 extrusion by multi-drug resistance cells. Cancer Lett. 1996;106:101–108
  29. Maia RC, Silva EAC, Harab RC, Lucena M, Pires V, Rumjanek VM. Sensitivity of vincristine-sensitive K562 and vincristine K562-Lucena 1 cells to anthracyclines and reversal of multi-drug resistance. Braz. J. Med. Biol. Res. 1996;29:467–472
  30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J. Immunol. Met. 1983;65:55–63
  31. van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, Reutelingsperger CPM. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidilserine exposure. Cytometry. 1998;31:1–9
  32. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, et al.  Correlation of multi-drug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multi-parameter flow cytometry: identification of discordant MDR−/efflux+ and MDR1+/efflux− cases. Blood. 1995;86(6):2329–2342
  33. Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie JP. P-gp and MRP activities using calcein-AM are prognostic factors in acute myeloid leukemia patients. Blood. 1998;91(12):4480–4488
  34. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistence to daunorubicin and with in vivo resistence in adult acute myeloid leukemia. Blood. 1999;94(3):1046–1056
  35. Hu XF, Slater A, Kantharidis P, Rischin D, Juneja S, Rossi R, et al.  Altered multi-drug resistence phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 1999;93(12):4086–4095
  36. Neyfalkh AA. Use of fluorescent dyes as molecular probes for the study of multi-drug resistance. Exp. Cell Res. 1988;174:168–176
  37. Twentyman PR, Rhodes T, Rayner S. A comparision of rhodamine-123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multi-drug resistance phenotypes. Eur. J. Cancer. 1994;30:1360–1369
  38. Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, et al.  DiOC2(3) is not a substrate for multi-drug resistance protein (MRP)-mediated drug efflux. Cytometry. 1996;25:14–20
  39. Huet S, Marie J-P, Gualde N, Robert J. Reference method for detection of P-gp mediated multi-drug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry. 1998;34:248–256
  40. Pallis M, Russel N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000;95(9):2897–2904
  41. van den Heuvel-Elbrink MM, Wiemer EAC, de Boevere MJ, van der Holt B, Vossebeld PJM, Pieters R, et al.  MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97(11):3605–3611
  42. Wuchter C, Karawajew L, Ruppert V, Schrappe M, Buchner T, Schoch C, et al.  Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711–721
  43. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 1991;139:271–279
  44. Steiner H, Polliack A, Kimchi-Sarfaty C, Libster D, Fibach E, Rund D. Differences in rhodamine-123 efflux in B-type chronic lymphocyte leukemia suggest possible gender and stage variations in drug resistance gene activity. Ann. Hematol. 1998;76(5):189–194
  45. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83(9):2451–2458
  46. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972;32:2643–2650
  47. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerases I and II inhibitors. Leukemia. 1995;9:1013–1024
  48. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from National Cancer Institute Anticancer Screen. Cancer Res. 1995;55:2116–2121
  49. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O’Connor PM, Kohn KW, et al.  Correlation between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996;56:4430–4437

PII: S0145-2126(02)00094-2

Leukemia Research
Volume 27, Issue 3 , Pages 243-251 , March 2003

Article Tools

* Image Usage & Resolution